Evox Therapeutics names new non-executive chairman
15 May 2020 -

Evox Therapeutics Ltd, an Oxford-based biotechnology company, has named Paul Carter as its new non-executive chairman, it was reported on Thursday.

Carter was earlier executive vice president, chief commercial officer at Gilead Sciences. He has also served as senior vice president, head of Commercial Operations International Markets with Gilead Sciences. Prior to that, he served at GlaxoSmithKline as regional vice president of China and Hong Kong. He has held various board positions and is presently a director at listed companies Hutchison China MediTech and Mallinkrodt Pharmaceuticals, and he was until recently a director of Alder Biopharma. He has also served as a retained advisor and board member for various private companies including Astorg Partners, Zambon Pharma, Indegene and Echosens.

Dr Antonin de Fougerolles, CEO of Evox, said, 'We are delighted to announce Paul's appointment as chairman of Evox. He has an outstanding track record of delivery across a long career in the industry. The addition of his commercial knowledge, strong network of contacts, and experience in creating partnerships will further strengthen the Evox team and help the company execute on its strategy of developing its own proprietary pipeline of exosome drugs.'